Cogent Biosciences, Inc. (COGT) |
|
10.11 0.07 (0.7%)
|
03-24 16:00 |
|
Open: |
9.94 |
Pre. Close: |
10.04 |
|
High:
|
10.28 |
Low:
|
9.935 |
|
Volume:
|
528,552 |
Market Cap:
|
707(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:24:59 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 14.19 One year: 16 |
| Support: |
Support1: 9.64 Support2: 8.02 |
| Resistance: |
Resistance1: 12.15 Resistance2: 13.69 |
| Pivot: |
11.67  |
| Moving Average: |
MA(5): 10.49 MA(20): 12.03
MA(100): 12.45 MA(250): 11.42  |
| MACD: |
MACD(12,26): -0.8 Signal(9): -0.6 |
| Stochastic oscillator: |
%K(14,3): 7.4 %D(3): 4.6 |
| RSI: |
RSI(14): 31.4 |
| 52-week: |
High: 18.06 Low: 3.78 |
| Average Vol(K): |
3-Month: 629 (K) 10-Days: 674 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ COGT ] has closed above bottom band by 10.4%. Bollinger Bands are 49.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
10.3 - 10.37 |
10.37 - 10.43 |
|
Low:
|
9.77 - 9.85 |
9.85 - 9.93 |
|
Close:
|
9.98 - 10.11 |
10.11 - 10.24 |
|
Company Description |
|
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Fri, 24 Mar 2023
Assenagon Asset Management S.A. Has $8.07 Million Position in ... - MarketBeat
Fri, 17 Mar 2023
Cogent Biosciences, Inc. (NASDAQ:COGT) Forecasted to Post ... - MarketBeat
Tue, 14 Mar 2023
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results - Yahoo Finance
Fri, 03 Mar 2023
MetLife Investment Management LLC increases its stake in Cogent ... - Best Stocks
Thu, 23 Feb 2023
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by ... - MarketBeat
Thu, 09 Feb 2023
Janus Henderson Group Cuts Stake in Cogent Biosciences (COGT) - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
70 (M) |
| Shares Float |
52 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
111 (%) |
|
Shares Short
|
5,540 (K) |
|
Shares Short P.Month
|
4,980 (K) |
Stock Financials |
|
EPS
|
-2.19 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.72 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-34.7 |
|
Return on Equity (ttm)
|
-59.7 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-1.74 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.11 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-119 (M) |
|
Levered Free Cash Flow
|
-67 (M) |
Stock Valuations |
|
PE Ratio
|
-4.64 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.71 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-5.97 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-11-08 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
